Hussain Mazhar, Atif Moazzam Ali, Ghafoor Muhammad Bilal
Department of Pharmacology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Pakistan.
Department of Pathology, Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Pakistan.
Pak J Pharm Sci. 2016 Nov;29(6 Suppl):2385-2389.
Obesity, dyslipidemia and hypertension are major risk factors for cardiovascular disease and its associated complications. To evaluate the beneficial effects of sitagliptin and metformin in non-diabetic dyslipidemic and hypertensive patients. A prospective randomized clinical trial was conducted on 70 newly diagnosed dyslipidemic patients with BMI > 25 and blood pressure > 130/80 at outpatient clinic of medical unit-1 of Sheikh Medical College/Hospital, Rahim Yar Khan. They were divided in to three groups each containing 35 patients; First group served as a healthy control while second and third study groups were given tablet sitagliptin 50mg and tab metformin 850mg respectively twice a day for twelve weeks. After three months treatment with sitagliptin and metformin there was significant reduction in body weight (Sitagliptin 6.5% vs Metformin 7.65%) and BMI (Sitagliptin 2.2% vs Metformin 2.8%) with p <0.05. Metformin caused a significant reduction in blood pressure with p < 0.05 (i.e. SBP 9.9% & DBP 6.4%) while sitagliptin caused a highly significant p <0.01 reduction in blood pressure (i.e. SBP 15.8% & DBP 12.2%). There was significant improvement in lipid profile with sitagliptin p<0.05. The percent reduction in value of TC, TG and LDL-C was 20.2%, 13.8% and 23.7% while HDL-C value was increased 11.2% respectively. There was highly significant improvement in lipid profile with metformin p<0.01. The percent reduction in value of TC, TG and LDL-C was 27.8%, 28.2% and 40.4% while HDL-C value was increased 16.8% respectively. Both drugs improve cardiometabolic risk factors independently in non-diabetic patients.
肥胖、血脂异常和高血压是心血管疾病及其相关并发症的主要危险因素。为了评估西他列汀和二甲双胍对非糖尿病血脂异常和高血压患者的有益作用。在拉希姆亚尔汗谢赫医学院/医院第一医疗单元门诊，对70名新诊断的BMI>25且血压>130/80的血脂异常患者进行了一项前瞻性随机临床试验。他们被分为三组，每组35名患者；第一组作为健康对照组，第二组和第三组研究组分别每天两次给予50mg西他列汀片和850mg二甲双胍片，持续12周。在用西他列汀和二甲双胍治疗三个月后，体重（西他列汀6.5% vs二甲双胍7.65%）和BMI（西他列汀2.2% vs二甲双胍2.8%）显著降低，p<0.05。二甲双胍使血压显著降低，p<0.05（即收缩压9.9%和舒张压6.4%），而西他列汀使血压极显著降低，p<0.01（即收缩压15.8%和舒张压12.2%）。西他列汀使血脂谱有显著改善，p<0.05。总胆固醇、甘油三酯和低密度脂蛋白胆固醇值的降低百分比分别为20.2%、13.8%和23.7%，而高密度脂蛋白胆固醇值分别升高11.2%。二甲双胍使血脂谱有极显著改善，p<0.01。总胆固醇、甘油三酯和低密度脂蛋白胆固醇值的降低百分比分别为27.8%、28.2%和40.4%，而高密度脂蛋白胆固醇值分别升高16.8%。两种药物均可独立改善非糖尿病患者的心脏代谢危险因素。
